Can a Two-Drug attack shrink Hard-to-Treat head and neck tumors?
NCT ID NCT06437522
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase II trial is testing whether a combination of an experimental drug (BL-B01D1) and a PD-1 monoclonal antibody can shrink tumors in people with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal type) and other solid tumors. The study enrolls about 46 adults aged 18 to 75 whose cancer has returned or spread. Researchers are measuring how many patients respond to the treatment and how long the response lasts, while also monitoring safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of an experimental drug called BL-B01D1 and a PD-1 monoclonal antibody
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced head and neck cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits are uncertain. The combination may cause significant side effects, and it may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a short course of immunotherapy and radiation shrink head and neck tumors before surgery?
- Could a genetic marker guide future cancer therapies in taiwan?
- Could a cheaper copy of keytruda work just as well against cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Can heat boost chemo? early trial tests thermotherapy for head and neck cancer